DNA hypermethylation in disease: mechanisms and clinical relevance
Open Access
- 8 July 2019
- journal article
- review article
- Published by Taylor & Francis in Epigenetics
- Vol. 14 (12) , 1141-1163
Abstract
Increasing numbers of studies implicate abnormal DNA methylation in cancer and many non-malignant diseases. This is consistent with numerous findings about differentiation-associated changes in DNA methylation at promoters, enhancers, gene bodies, and sites that control higher-order chromatin structure. Abnormal increases or decreases in DNA methylation contribute to or are markers for cancer formation and tumour progression. Aberrant DNA methylation is also associated with neurological diseases, immunological diseases, atherosclerosis, and osteoporosis. In this review, I discuss DNA hypermethylation in disease and its interrelationships with normal development as well as proposed mechanisms for the origin of and pathogenic consequences of disease-associated hypermethylation. Disease-linked DNA hypermethylation can help drive oncogenesis partly by its effects on cancer stem cells and by the CpG island methylator phenotype (CIMP); atherosclerosis by disease-related cell transdifferentiation; autoimmune and neurological diseases through abnormal perturbations of cell memory; and diverse age-associated diseases by age-related accumulation of epigenetic alterations.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR001417)
- National Institutes of Health (NS04885)
- National Institutes of Health (R01AR069055)
- National Institutes of Health (U19AG055373)
- Louisiana Cancer Center (No number)
This publication has 164 references indexed in Scilit:
- Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognitionCell Research, 2013
- Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized DerivativesCell, 2013
- Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancerGenome Research, 2011
- Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genesGenome Research, 2011
- Increased methylation variation in epigenetic domains across cancer typesNature Genetics, 2011
- Genome-scale analysis of aberrant DNA methylation in colorectal cancerGenome Research, 2011
- Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genomeNature Genetics, 2007
- CpG island methylator phenotype in cancerNature Reviews Cancer, 2004
- Hypomethylation and hypermethylation of DNA in Wilms tumorsOncogene, 2002
- DNA methylation in cancer: too much, but also too littleOncogene, 2002